JP2018522594A - 抗腫瘍治療のための、トランスインフェクションさせたリンパ球 - Google Patents

抗腫瘍治療のための、トランスインフェクションさせたリンパ球 Download PDF

Info

Publication number
JP2018522594A
JP2018522594A JP2018525816A JP2018525816A JP2018522594A JP 2018522594 A JP2018522594 A JP 2018522594A JP 2018525816 A JP2018525816 A JP 2018525816A JP 2018525816 A JP2018525816 A JP 2018525816A JP 2018522594 A JP2018522594 A JP 2018522594A
Authority
JP
Japan
Prior art keywords
cells
tumor
cancer
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522594A5 (cg-RX-API-DMAC10.html
Inventor
チャコン，エステーバン ベイガ
チャコン，エステーバン ベイガ
アダリア，アランサス クルス
アダリア，アランサス クルス
サンティアゴ，ギイェルモ ラミレス
サンティアゴ，ギイェルモ ラミレス
サンチェス，バルビノ アラルコン
サンチェス，バルビノ アラルコン
マドリッド，フランシスコ サンチェス
マドリッド，フランシスコ サンチェス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Original Assignee
Consejo Superior de Investigaciones Científicas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas filed Critical Consejo Superior de Investigaciones Científicas
Publication of JP2018522594A publication Critical patent/JP2018522594A/ja
Publication of JP2018522594A5 publication Critical patent/JP2018522594A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018525816A 2015-08-07 2016-08-08 抗腫瘍治療のための、トランスインフェクションさせたリンパ球 Pending JP2018522594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201531177 2015-08-07
ESP201531177 2015-08-07
PCT/ES2016/070597 WO2017025657A1 (es) 2015-08-07 2016-08-08 Linfocitos transinfectados para terapia anti-tumoral

Publications (2)

Publication Number Publication Date
JP2018522594A true JP2018522594A (ja) 2018-08-16
JP2018522594A5 JP2018522594A5 (cg-RX-API-DMAC10.html) 2019-09-12

Family

ID=56936436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525816A Pending JP2018522594A (ja) 2015-08-07 2016-08-08 抗腫瘍治療のための、トランスインフェクションさせたリンパ球

Country Status (6)

Country Link
US (1) US20180228840A1 (cg-RX-API-DMAC10.html)
EP (1) EP3333255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018522594A (cg-RX-API-DMAC10.html)
AU (1) AU2016307370A1 (cg-RX-API-DMAC10.html)
CA (1) CA2995021A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017025657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12087428B2 (en) * 2020-12-29 2024-09-10 Kpn Innovations Llc Systems and methods for generating a body degradation reduction program

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRUZ-ADALIA ARANZAZU; ET AL: "T CELLS KILL BACTERIA CAPTURED BY TRANSINFECTION FROM DENDRITIC CELLS AND CONFER PROTECTION IN MICE", CELL HOST & MICROBE, vol. VOL:15, NR:5, JPN5018005882, 14 May 2014 (2014-05-14), NL, pages 611 - 622, ISSN: 0004448302 *
MOJCA SKOBERNE; ET AL: "KBMA LISTERIA MONOCYTOGENES IS AN EFFECTIVE VECTOR FOR DC-MEDIATED INDUCTION OF ANTITUMOR IMMUNITY", JOURNAL OF CLINICAL INVESTIGATION, vol. VOL:118, NR:12, JPN5018005881, December 2008 (2008-12-01), US, pages 1 - 12, ISSN: 0004448303 *

Also Published As

Publication number Publication date
WO2017025657A1 (es) 2017-02-16
CA2995021A1 (en) 2017-02-16
EP3333255A1 (en) 2018-06-13
US20180228840A1 (en) 2018-08-16
AU2016307370A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
JP7452929B2 (ja) 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
JP6207783B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
Harimoto et al. Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells
Palucka et al. Dendritic cells: a critical player in cancer therapy?
AU2007269245B2 (en) Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
Cruz-Adalia et al. Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses
Ghinnagow et al. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
US8475785B2 (en) Allogeneic cancer cell-based immunotherapy
JP2017507922A (ja) 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
EP3333255A1 (en) Transinfected lymphocytes for anti-tumor therapy
JP7525109B2 (ja) Ｃｄ１３５＋細胞を含む医薬組成物
JP7146732B2 (ja) 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
KR101506426B1 (ko) 화학적 고정화를 통해 안정화된 미세 막상 t 세포 백신 제조방법
Veiga et al. Lymphocytes transfectes pour therapie antitumorale
US20150104477A1 (en) Ubiquitinylated proteins
Wu Functions of cDC1 in Mediating CD4+ Help for CD8+ T cells
Shute Glycolipid-Loaded Nanoparticles Harness Invariant Natural Killer T Cells for Tumor Immunotherapy
Bolton et al. Transplantation immunology
Buchta Mechanisms of TLR signaling and cooperation in B lymphocytes
Zhang Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling
Kline The Innate Immune System Drives T Cell Tolerance Against Acute Myeloid Leukemia
Barsoumian SA-4-1BBL as a modulator of innate, adaptive, and regulatory immunity: implications for cancer prevention and treatment.
EA040420B1 (ru) Универсальная клетка т-киллер

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210224